Osthoff, Michael http://orcid.org/0000-0001-5439-957X
Jaeger, Veronika K.
Heijnen, Ingmar A. F. M.
Trendelenburg, Marten
Jordan, Suzana
Distler, Oliver
Walker, Ulrich A.
Article History
Received: 28 November 2018
Accepted: 5 March 2019
First Online: 18 March 2019
Ethics approval and consent to participate
: Approved by the Ethics Committee at participating Basel and Zurich University EUSTAR centers, patients were required to provide informed written consent.
: Not applicable.
: OD has/had consultancy relationship and/or has received research funding from Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, espeRare foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi, Serodapharm, and UCB in the area of potential treatments of scleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of systemic sclerosis licensed. MO, IH, SJ, VJ, and UAW declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.